New thoughts on the initiation of mucositis

Oral Diseases

Volumn 16, Issue 7, 2010, Pages 597-600

  Sonis, S T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

DAMP; mucositis; PAMP; pathobiology

Indexed keywords

REACTIVE OXYGEN METABOLITE;

CELL CLONE; CELL DEATH; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION HAZARD; RADIATION RESPONSE; REVIEW; RISK ASSESSMENT; TOXICITY;

CELL DEATH; CLONE CELLS; EPITHELIAL CELLS; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; MOUTH MUCOSA; NEOPLASMS; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; STOMATITIS;

EID: 77956853059     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01681.x     Document Type: Review

References (41)

1. Andersson UG, Tracey KJ (2004). HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J Intern Med 255 : 318 319.
2. Aprile G, Ramoni M, Keefe D et al (2008). Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112 : 284 293.
3. Bahri R, Saidane-Mosbahi D, Rouabhia M (2010). Candida famata modulates toll-like receptor, beta-defensin, and proinflammatory cytokine expression by normal human epithelial cells. J Cell Physiol 222 : 209 218.
4. Bianchi ME (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J Leuk Biol 81 : 1 5.
5. Bogunia-Kubik K, Polak M, Lange A (2003). TNF polymorphisms are associated with toxic but not aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32 : 617 622.
6. Bonan PRF, Kaminagakura E, Pires FR et al (2007). Histomorphometry and immunohistochemical features of grade 1 (WHO) oral radiomucositis. Oral Dis 13 : 170 176.
7. Braun MS, Richman SD, Thompson L et al (2009). Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27 : 5519 5528.
8. Dorr W, Heider K, Spekl K (2005). Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol 81 : 557 565.
9. Etiz D, Erkal HS, Serin M et al (2000). Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 36 : 116 120.
10. Fukata M, Vamadevan AS, Abreu MT (2009). Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 21 : 242 253.
11. Handschel J, Sunderkotter C, Prott FJ et al (2001). Increase in RM31-positive macrophages in radiation induced oral mucositis. J Pathol 193 : 242 247.
12. Jakobsen A, Nielsen JN, Glydenkerne N et al (2005). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 : 1365 1369.
13. Janeway CA, Medzhitov R (2002). Innate immune recognition. Ann Rev Immunol 20 : 197 216.
14. Lalla RV, Pilbeam CC, Walsh SJ et al (2010). Role of cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer in press.
15. Lecomte T, Ferraz JM, Zinzindohoue F et al (2004). Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouacil-based chemotherapy. Clin Cancer Res 10 : 5880 5888.
16. Lockhart PB, Sonis ST (1979). Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg, Oral Med, Oral Pathol 48 : 21 28.
17. Logan RM, Gibson RJ, Sonis ST et al (2007). Nuclear factor-kappaB (NF-happaB) and cycloxygenase-2 (COX-2) expression in oral mucosa following cancer chemotherapy. Oral Oncol 43 : 395 401.
18. Logan RM, Stringer AM, Bowen JM et al (2008). Serum levels of NF-B and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7 : 1139 1145.
19. Lopes NN, Plapler H, Chavantes MC et al (2009). Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer 17 : 1409 1415.
20. Lotze MT, Zeh MJ, Rubartelli A et al (2007). The grateful dead: damage-associated molecular pattern molecules and reductionoxidation regulate immunity. Immunol Rev 220 : 60 81.
21. Matzinger P (2002). The danger model: a renewed sense of self. Science 296 : 301 305.
22. Mothersill C, Seymour CB (2004). Radiation-induced bystander effects-implications for cancer. Nat Rev Cancer 4 : 158 164.
23. Nonzee NJ, Dandade NA, Patel U et al (2008). Evaluating the supportive costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Cost of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer center. Cancer 113 : 1446 1452.
24. Palm NW, Nedzhitov R (2009). Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227 : 221 233.
25. Paris F, Fuks Z, Kang A et al (2001). Endothelial apoptosis as the primary lesion initiating intestinal damage in mice. Science 293 : 293 297.
26. Park JS, Svetkauskaite D, He Q et al (2004). Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279 : 7370 7377.
27. Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001). Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1 : 65 70.
28. Schmidt AM, Hori O, Cao R et al (1996). RAGE: a novel cellular receptor for advanced glycation and products. Diabetes 45 (Suppl. 3 77 80.
29. Schwab M, Zanger UM, Marx C et al (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26 : 2131 2138.
30. Smith KP, Luong MX, Stein GS (2009). Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol 220 : 21 29.
31. Sonis ST (1998). Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 : 39 43.
32. Sonis ST (2002). The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13 : 380 389.
33. Sonis ST (2004). The pathobiology of mucositis. Nat Rev Cancer 4 : 277 284.
34. Sonis ST (2009). Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45 : 1015 1020.
35. Sonis ST, Peterson RL, Edwards LJ et al (2000). Defining mechanisms of action of Interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36 : 373 381.
36. Sonis ST, Scherer J, Phelan S et al (2002). The gene expression sequence in an animal model of acute radiation-induced oral mucositis. Cell Prolif 35 (Suppl. 1 93 102.
37. Sonis ST, ODonnell KE, Popat R et al (2004). The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40 : 170 176.
38. Sonis ST, Haddad R, Posner M et al (2007). Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43 : 289 300.
39. Srikrishna G, Freeze HH (2009). Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11 : 615 628.
40. Yeoh AS, Gibson RJ, Yeoh EE et al (2007). A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther 6 : 2319 2327.
41. Zunt SL, Burton LV, Goldblatt LI et al (2009). Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumor necrosis factor-alpha secretion by macrophage-like cells. Clin Exp Immunol 156 : 285 293.